PMV Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $67.00M
- P/E (TTM)
- –
- Dividend yield
- –
About PMV Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
PMV Pharmaceuticals is a precision oncology company that discovers and develops small molecule, tumor-agnostic therapies targeting mutant p53 proteins to restore their normal tumor-suppressing function. The company's lead product candidate is rezatapopt, an orally administered small molecule designed to structurally correct misfolded p53 proteins carrying the Y220C mutation. Rezatapopt aims to treat patients with advanced or metastatic solid tumors harboring this mutation, including ovarian, endometrial, breast, non-small cell lung, colorectal, and pancreatic cancers.
The company operates in the United States and conducts clinical evaluations, including its pivotal PYNNACLE clinical trial. Its principal executive offices and headquarters are located in Princeton, New Jersey.
Summary of the business section of PMV Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PMV Pharmaceuticals, Inc.
- Headquarters
- Princeton, NJ
- Address
- 400 Alexander Park Drive, Suite 301 08540
- Phone
- (609) 642-6670
- Website
- pmvpharma.com
- Employees
- 54, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- PMVP
- Exchange
- Nasdaq
- IPO date
- Sep 25, 2020
- Shares outstanding
- 53M, Aug 14, 2026
- Public float
- $53.44M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1699382
- CUSIP
- 69353Y103
- ISIN
- US69353Y1038
- EIN
- 46-3218129
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Henry Mack | President and CEO, Director | 904,691 |
| Michael Carulli | Chief Financial Officer | 73,848 |
| Robert Ticktin | General Counsel & COO | 98,695 |
| Deepika Jalota | Chief Development Officer | 89,959 |
| Kirsten Flowers | Director | – |
| Charles M. Baum | Director | – |
| Arnold J. Levine | Director | 409,842 |
| Carol Giltner Gallagher | Director | – |
| Laurie Stelzer | Director | – |
| Richard A. Heyman | Director | 558 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David H. Mack, Ph.D. | $1.67M | $958.18K | $898.20K | $14 | – |
| FY2024 David H. Mack, Ph.D. | $4.76M | $2.17M | $1.65M | $7 | – |
| FY2023 David H. Mack, Ph.D. | $2.21M | $513.65K | $1.18M | $13 | – |
| FY2022 David H. Mack, Ph.D. | $3.58M | -$519.25K | $2.13M | $38 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 6, 2026 , we had 54 full-time employees, including 18 employees with Ph.D., M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 25, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 21, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |